Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,201–14,300 of 15,747
Forero-Peña, D. A., Leyva, J. L., Valenzuela, M. V., Omaña‐Ávila, Ó. D., Regalado-Gutiérrez, O. A., Mendoza-Millán, D. L., Sánchez-Ytriago, E. A., Hachem, A. C. L.-E., Farro, K. R., Maita, A. K., et al. (2024) · Discover Public Health · doi:10.1186/s12982-024-00259-x · Cited by 1
mRNA Vaccines as Member of Biotechnology-Based Vaccines
Harisa, G. I., & Alzahrani, M. M. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_15
van der Pol, S., Beck, E. C., Westra, T. A., Postma, M. J., & Boersma, C. (2026) · Vaccines · doi:10.3390/vaccines14040364
Genetically-encoded degraders as versatile modulators of intracellular therapeutic targets
Dai, C., Wang, J., Tu, L., Pan, Z., Yang, J., Zhou, S. Y., Luo, Q., Zhu, L., & Ye, Y. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100458 · Cited by 1
Chemotherapy and COVID-19 Vaccination in Patients With Gastrointestinal Cancer
Suenaga, M., Yamauchi, S., Morikawa, R., et al. (2024) · In Vivo · doi:10.21873/invivo.13566
Agent-Based Model of the Impact of Higher Influenza Vaccine Efficacy on Seasonal Influenza BurdenPreprint
Krauland, M. G., Zimmerman, R. K., Williams, K. V., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4113831
Hajimiri, K., Shoghli, A., Hoseinzade, Z., Gouya, M. M., Zahraei, S. M., Mahmoudi, S., Hoveidamanesh, S., Mohamadi, S., Bigdeli, Z., Farsadeghi, M., et al. (2023) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580231168494
Habib, G., Yousuf, H., Bredius, L., Gorp, E. C. M. V., Scherder, E., van Essen, T., Elferink, T., van der Linden, S., Narula, J., & Hofstra, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4671828
Erratum to: Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?
Harper, J., Betts, M. R., Lichterfeld, M. D., Müller-Trutwin, M. C., Margolis, D. M., Bar, K. J., Li, J. Z., McCune, J. M., Lewin, S. R., Kulpa, D. A., et al. (2024) · Pathogens and Immunity · doi:10.20411/pai.v8i2.696
Iwakawa, S., Azechi, T., Saigo, O., Imai, R., Nakai, A., Koshiba, S., Saito, U., Asakura, K., Sato, K., & Kimura, T. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00338-w
“Several surveys in the general population have shown that the frequency of adverse events of COVID-19 vaccine, such as fever and fatigue, increased after the second dose compared with the first dose [4, 12].”
BackgroundResultSevere maxillary pain after Covid-19 vaccination
Schattner, A., & Dubin, I. (2022) · European Journal of Oral and Maxillofacial Surgery · doi:10.23736/s2532-3466.22.00300-9
Balgos, A., Hannawi, S., Chen, W. K., Abuquta, A., Safeldin, L., Hassan, A., Alamadi, A., Tirador, L. S., Jaen, A. M., Villalobos, R. E., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2334423
“Additionally, subjects were followed up for safety and immunogenicity for 6 months post-boosting in both studies, with final analyses conducted accordingly [9,10].”
Ethnicity and sub-Saharan African representation in the emergency development of covid-19 vaccines
Taylor, A. E., Millard, G., Packham, A., Ngabonziza, J. C. S., Muvunyi, C. M., & Green, C. (2025) · BMJ Medicine · doi:10.1136/bmjmed-2023-000780
Amin, B. H., & Muhammed, O. (2023) · Journal of Zankoy Sulaimani - Part A · doi:10.17656/jzs.10935
What are the rates of adverse events in patients who receive mRNA COVID vaccines?
Hess, M. C., Vondrak, E., & Fray, S. (2022) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001713
Case report: Myositis causing isolated neck extensor myopathy (INEM) exacerbated after vaccinationPreprint
Holm-Yildiz, S. D., Pedersen, B. S., Kodal, L. S., & Dysgaard, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2835580/v1
Dosis aplicadas contra COVID-19 por laboratorio en las entidades territoriales de Colombia
Pinzón, J. E. D. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1278
Takano, T., Matsumura, T., & Takahashi, Y. (2026) · International Immunology · doi:10.1093/intimm/dxag040 · Cited by 1
Ali, H., & Naz, S. (2026) · Knowledge Management Research & Practice · doi:10.1080/14778238.2026.2648163
Yang, P. C., Dickert, N. W., Haczku, A., et al. (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000000930
Genetics, genetic profiles, and Jewish law
Weissinger, Y., & Barilan, Y. M. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0018
Known Vaccine-Associated Adverse Events
Tilak, K., Adams, F., & Harrison, C. J. (2026) · Springer eBooks · doi:10.1007/978-1-0716-5464-4_3
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
(2021) · doi:10.1101/2021.09.14.21262309
“Intense research has resulted in the generation of highly 42 effective vaccines for the prevention of COVID-19 related hospitalization and death (1-5).”
BackgroundCOVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines induces nasal neutralizing antibodiesPreprint
Gevaert, P., Declercq, J., Tobback, E., et al. (2021) · doi:10.22541/au.162648429.99050725/v1
“to date, several vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) have proven to effectively reduce severe illness (1,2).”
Backgroundde Castro, A. A., de Assis, L. C., Appel, R. J. C., da Cunha, E. F. F., Nepovimová, E., Kuča, K., Ramalho, T. C., & Porta, F. A. L. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111046
Sábato, S., Benet, S., Rogers, A. J., Murray, T. A., Skeans, M. A., Mothe, B., Paredes, R., Mourad, A., Kiweewa, F., Kamel, D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92742-x
O’Brian, M. R. (2024) · The Conversation · doi:10.64628/aai.ct6uuje7c
COVID-19 Pandemic and Contamination Response
Hazeltine, M. D., & Hirsh, M. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-96542-6_3
Morin‐Dewaele, M. (2023) · theses.fr (ABES) · doi:10.70675/3332ee05z67cez489cza3e8zb3843eed7d42
Yu, T., Wang, Y., Kong, Y., Wang, J., Hong, Y., Wang, Y., Hu, F., Zhu, Z., & Yuan, H. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501497 · Cited by 3
Konnova, A., Winter, F. D., Gupta, A., et al. (2022) · medRxiv · doi:10.1101/2022.09.25.22280267
Morse, S. S., Kawachi, I. I., & Duncan, D. T. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780197625217.003.0001
Lange, B., Welker, S., Kittel, M., Jabbour, C., Reindl, W., Walter, T., & Heininger, A. (2022) · Infection · doi:10.1007/s15010-022-01797-9
“In Germany, the mRNA vaccine BNT162b2 (Pfizer-BioNTech) was applied quite predominantly, for which a protective effect for 95% of the vaccinated against the wild type of SARS-CoV-2 was described [4].”
BackgroundKorves, C., Kulldorff, M., Balajee, A., Smith, J., Zwain, G., Graham, D. J., Whitaker, H., & Izurieta, H. S. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127658 · Cited by 1
Peptide–Lipid Nanoparticles Enhance Cell Transfection Efficiency
Ye, Y., Hu, H., Yue, L., Su, R., Qi, W., & Wang, Y. (2026) · Langmuir · doi:10.1021/acs.langmuir.5c05962
Ali, M. T., Chapra, A. F., Mohamed, S., Ghareeb, A. N., Kuwari, M. A., Karim, S. A., Hamid, T., Hassan, E. A. A., Qahtani, A. A., Asaad, N., et al. (2024) · Heart Views · doi:10.4103/heartviews.heartviews_62_24
(2000) · Time to knit · doi:10.1016/s1166-8598(22)89662-9
The efficacy and safety of COVID-19 vaccine: A protocol of systematic review and meta-analysisPreprint
Xue, X., Deng, Z., Li, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-379876/v1
Limeilati, N. A., Nidom, R. V., Sari, T. T., Kusumarahayu, N. P., Fransiska, S. V., Indrasari, S., Garmana, A. N., Ayuningtyas, D. K., Nugroho, G. S., Darsono, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.18.629000 · Cited by 1
Sen, S., Prusty, P. K., Rawat, A., Gurajala, S., Jyothikiran, H., & Rathi, R. K. (2024) · Multidisciplinary Reviews · doi:10.31893/multirev.2023ss003
Boldyrev, I. A., Shendrikov, V. P., Vostrova, A. G., et al. (2023) · Биоорганическая химия · doi:10.31857/s0132342323020069
de Família, M., Santos, P., Maricoto, T., et al. (2021) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v37i4.13323
Bhatt, U., Hérate, C., Estelien, R., Relouzat, F., Dereuddre‐Bosquet, N., Maciorowski, D., Diop, C., Couto, E., Staiti, J., Cavarelli, M., et al. (2024) · Vaccines · doi:10.3390/vaccines12080882
SARS-CoV-2 mRNA Vaccination Induces Reduced T-Cell Apoptosis in Patients with Solid Tumors
Belda-Marco, A., Serrano-García, L., Moret, A., Fresneda‐Portillo, C., Domínguez-Márquez, M. V., Comes-Raga, A., Jávega, B., O’Connor, J., Andreu‐Ballester, J. C., Llombart‐Cussac, A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146173
Perspective Chapter: Prevention of COVID-19 at Our University
Maeshima, S., Nomura, R., Nogami, E., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102338
Lorent, D., Nowak, R., Jankowska, M., Kuszel, Ł., & Zmora, P. (2023) · Vaccines · doi:10.3390/vaccines11010118
“The clinical trials demonstrated a 52% efficacy in preventing COVID-19 after the first vaccine dose and 95% after the full vaccination [17], which lasted up to six months.”
The Influence of a COVID-19 Vaccine Mandate on Vaccination Rates in a University Setting
Brandstetter, E., Bohn, B., Oakes, J. M., & Demmer, R. T. (2024) · American Journal of Public Health · doi:10.2105/ajph.2024.307804
ERKAN, S., Aytac, H. O., Ozdemir, H., Avcı, T., GÜNDOĞDU, R., Kus, M. M., Güneşli, A., Pehlivan, U. A., & Yalçın, Ç. (2025) · Medicine · doi:10.1097/md.0000000000043151
Pimenta, P. D. C., Geraldine, V. G. S., Lima, T. C. D. A., et al. (2025) · Discover Public Health · doi:10.1186/s12982-024-00380-x
O Novo Normal na EAD: Relato de Práticas Inovadoras em meio à Pandemia
Freitas, H. C., Vieira, C. D. O., Barbosa, L. G., Bisinotto, S. D. D. S., Silva, F. C. M. E., & Moreira, S. M. D. N. (2021) · Uniedusul Editora eBooks · doi:10.51324/86010749.3
Ko, H. Y., Yoon, D., Kim, J. H., Jeong, H. E., Hong, S. B., Shin, W. C., Shin, J. Y., & on behalf of the CoVaSC Investigators (2025) · Epidemiology and Health · doi:10.4178/epih.e2025024
“…vaccines utilize platforms such as live attenuated or inactivated vaccines, whereas the COVID-19 vaccines studied here employ newer platforms, including lipid nanoparticle-encapsulated nucleoside-modified RNA vaccines (BNT162b2, mRNA-1273) [26,27], viral vector vaccines (ChAdOx1 nCoV-19, Ad26.”
Ahmad, F., Naeem, M., Khalid, A. R., Ahmed, S., Nadeem, M. F., Usman, M., Amjad, N., Ijaz, M., Mahmood, S., & Kanwal, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-9481803/v1
Vicentini, M., Mancuso, P., Venturelli, F., Mezzadri, S., Bisaccia, E., Zerbini, A., Mangone, L., Rossi, P. G., & on behalf of the Reggio Emilia COVID-19 Working Group (2025) · Vaccines · doi:10.3390/vaccines13121223
“Studies have demonstrated the efficacy of COVID-19 vaccination in reducing the severity of disease and mortality rates across various populations [6].”
Raczkiewicz, P., Zaremba, B., Śmiech, N., Nowakowska, K., Lewkowicz, M., & Trojnar, M. P. (2021) · Journal of Education Health and Sport · doi:10.12775/35062 · Cited by 1
Tiroiditis subaguda y tirotoxicosis posterior a vacuna contra SARS-CoV-2: reporte de 2 casos
Rueda-Galvis, M. V., Ramírez‐Sánchez, I. C., Builes-Montaño, C. E., & Hoyos, A. V. (2022) · Medicina y Laboratorio · doi:10.36384/01232576.609 · Cited by 1
Wang, C., Zang, Y., Yang, J., Yang, K., Zhao, Y., Zhang, W., Guo, S., Han, C., Liu, C., Mi, X., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5252903
A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection
Huang, S., Urbina, A. N., Chen, Y. A., & Wang, S. (2021) · Pathogens · doi:10.3390/pathogens10091078
Kwakye, I. N., Adom-Fynn, D., Kugbey, N., & Bour, K. B. (2025) · SAGE Open · doi:10.1177/21582440251342094 · Cited by 1
“Public health experts advocate for vaccination to reduce virus transmission and severe outcomes (Wang et al., 2021), supported by evidence of the effectiveness of vaccines in reducing transmission and protecting against severe disease (Dagan et al., 2021; Polack et al., 2020).”
Machine Learning-guided Prediction of Ionizable Amphiphilic Janus Dendrimers for mRNA Nanomedicine
Cheng, W.-T., Zheng, H.-L., Zhu, P.-Y., Hao, J., Zhang, D., & Li, Y.-S. (2026) · Chinese Journal of Polymer Science · doi:10.1007/s10118-026-3563-3
Cappellacci, F., Anedda, G., Giacco, S. D., Coghe, F., Cappai, R., Canu, G. L., Erdas, E., Calò, P. G., Medas, F., & Firinu, D. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102375 · Cited by 1
Effectiveness and Safety of COVID-19 Vaccine
Nishi, J. (2021) · TRENDS IN THE SCIENCES · doi:10.5363/tits.26.10_18
Construction of Lipid Nanoparticles Based on Natural Molecules for Safe and Efficient mRNA Delivery
Zhong, T., Li, H., Xu, J., Zeng, F., & Wu, S. (2026) · BioNanoScience · doi:10.1007/s12668-026-02577-7
Viral and Immunological Characteristics of COVID-19 Vaccine Breakthrough InfectionsPreprint
Arashiro, T., Kanno, T., Miyamoto, S., Saito, S., Moriyama, S., Sekizuka, T., Kanou, K., Stucky, A., Iida, S., Ainai, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-783083/v1
Xue, S., He, S., Huang, Z., Yang, M., Hu, G., Chen, X., Chen, Q., Zhou, W., Lin, S., & Chen, S. (2025) · Communications Biology · doi:10.1038/s42003-025-08648-x · Cited by 1
Delrue, L., Muylaert, A., Beernaert, A., Pelsmaeker, I. D., Boel, E., Moyá, A., Verstreken, S., Dierckx, R., Heggermont, W., Bartúnek, J., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12092148
“Fortunately, vaccines to prevent coronavirus disease 2019 (COVID-19) have been shown to generate specific immune responses to viral antigens and neutralizing antibodies and reduce the risk and severity of symptomatic disease [2].”
BackgroundEvaluation of Post–vaccination Symptoms of COVID 19 Vaccines among People in Basrah- Iraq Society
Thamer, A. K. (2022) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v16i3.18256
(2023) · Journal of Clinical & Experimental Immunology · doi:10.33140/jcei.08.02.04
Immunological Evaluation of mRNA‐LNP Vaccines Targeting Conserved S2 and NSP3 Domains of SARS‐CoV‐2
Begum, F., Mallik, M. H., Ghora, S., & Ray, U. (2026) · Biotechnology Journal · doi:10.1002/biot.70294
“The COVID-19 vaccines BNT162b2 and mRNA-1273 are based on the full-length SARS-CoV-2 spike (S) glycoprotein, modified to retain its prefusion conformation [6, 7, 4].”
Synonymous mutations in viral evolution and vaccine design
Shan, K.-J., Tang, X., Wang, Y., Wang, Z., & Lü, J. (2026) · Trends in Microbiology · doi:10.1016/j.tim.2026.04.010 · Cited by 1
Nickel, K. B., Fraser, V. J., Babcock, H. M., & Kwon, J. H. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.299
(2026) · Elsevier eBooks · doi:10.1016/b978-0-44-355525-1.00020-5
Cause or Consequence? What is the Relationship between Cardiac Injury and COVID-19 Severity?
Mesquita, C. T. (2021) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20210270
Design Strategies and Recent Advances in Self-Immolative Lipid Nanoparticles for mRNA Delivery
王, 卓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662330
Castellanos-Hernández, D. I., Mayoral-Chávez, M. A., Matias‐Cervantes, C. A., & Alpuche, J. J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1752169
Nagy, H., Hameed, M., Khan, F., Co, E. L., & Rauf, U. (2023) · Avicenna Journal of Medicine · doi:10.1055/s-0042-1760338
Fleury, H. J. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-78221-3.00008-2
Singh, S., Dahiya, S., Singh, Y. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.13.426537
Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment
Masago, K., & Fujita, S. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.002
Ogbodo, S. C., Damba, J. J., Olaoye, O. C., & Ofili, D.-F. C. (2024) · Research Square · doi:10.21203/rs.3.rs-4934548/v1
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudyPreprint
Khan, Q. J., Bivona, C. R., Martin, G. A., Zhang, J., Liu, B., He, J., Li, K. H., Nelson, M., Williamson, S. K., Doolittle, G. C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3936503
A systematic review and meta-analysis of risk factors for long COVIDPreprint
Nakagawara, K., Otake, S., Horita, N., Namkoong, H., Terai, H., Takemura, R., Nagashima, K., Chubachi, S., & Fukunaga, K. (2025) · Research Square · doi:10.21203/rs.3.rs-7667974/v1
Awakening Sleeping Beauties from articles on mRNA vaccines against COVID-19
Chaleplioglou, A., Selinopoulou, E., Kyprianos, K., & Koulouris, A. (2026) · Scientometrics · doi:10.1007/s11192-026-05598-x · Cited by 1
“The development and worldwide vaccination of human populations with the mRNA vaccines BNT162b2 by Pfizer-BioNTech (Polack et al., 2020) and mRNA-1273 by Moderna (Baden et al., 2021) represent disruptive applications of an existing, but not widely produced or tested, technology.”
Wang, W., Wang, J., Jia, R., Martini, S., Liu, J., Huang, Y., Wang, F., Qi, X., & Fu, J. (2023) · Portal hypertension & cirrhosis · doi:10.1002/poh2.49
Prasad‐Reddy, L., Dahal, A., & Zimmer, A. J. (2026) · Springer eBooks · doi:10.1007/978-1-0716-5464-4_15
COVID- 19 and Transplantation in India
Anandh, U. (2022) · Medical Research Archives · doi:10.18103/mra.v10i6.2867
The Effect of COVID-19 and Its Vaccination in Psoriasis Exacerbation
Xenopoulou, D., Ratkiewicz, A., & AlEdani, E. M. (2025) · Updates in clinical dermatology · doi:10.1007/978-3-031-87791-9_3
Adult-Onset Still’s Disease after COVID-19 Vaccination: A Case Report and Review
Park, J. W., & Lee, S. W. (2023) · Soonchunhyang Medical Science · doi:10.15746/sms.23.002
“As the number of COVID-19 vaccinations increases, cases of severe side effects to messenger RNA (mRNA) vaccines, which were not reported at the time of clinical trials, are being observed [5,6].”
BackgroundIoannou, G. N., Locke, E. R., Green, P. K., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4003207
Syenina, A., Gan, E. S., Toh, J. Z. N., de Alwis, R., Lin, L. Z., Tham, C. Y. L., Yee, J. X., Leong, Y. S., Sam, H., Cheong, C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985604
Taniguchi, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.2070
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.